Amendments for: 033-2020-2021-Q3-815733

Current (Nov 24, 2023)
Agreement Value: $169,872,474.00
Agreement: Medicago Proposal to fill Canada's pandemic preparedness gap (815733). Oct 17, 2020 - Apr 1, 2043

The Project was planned to be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.

Expected Results:

The company had planned to secure up to 76 million doses of Medicago’s COVID-19 vaccine candidate, enough to vaccinate 38 million people. Medicago had committed to creating 75 jobs and maintaining 275 over the term.

Organization: Innovation, Science and Economic Development Canada
Recipient: Medicago inc. (For-profit organization)
Location: Quebec, Quebec, CA G1V3V9
Type: Contribution
Additional Information:

The amendment has been completed to terminate by mutual consent Medicago’s contribution agreement.

Recipient's Operating Name: Medicago inc.
Federal Riding Name: Louis-Hébert (24044)
Program Name: SIF Stream3- Attraction

-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.

NAICS Code: 541710